Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $420
1 Year Target Price $420
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.93M USD | Price to earnings Ratio - | 1Y Target Price 420 |
Price to earnings Ratio - | 1Y Target Price 420 | ||
Volume (30-day avg) 1 | Beta 5.73 | 52 Weeks Range 2.81 - 485.37 | Updated Date 06/30/2025 |
52 Weeks Range 2.81 - 485.37 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -325.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -115.99% | Return on Equity (TTM) -1023.93% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value 12213400 | Price to Sales(TTM) 1.61 |
Enterprise Value 12213400 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 3224160 | Shares Floating 374281 |
Shares Outstanding 3224160 | Shares Floating 374281 | ||
Percent Insiders 9.95 | Percent Institutions 0.43 |
Analyst Ratings
Rating 1 | Target Price 420 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was founded in 2016 as a spin-off from Emergent BioSolutions. It focuses on developing novel immunotherapies for cancer and autoimmune diseases.
Core Business Areas
- ADAPTIR Platform: Aptevo's core technology platform for generating novel biologic therapeutics.
- Hematology: Developing and commercializing products for hematological malignancies.
- Autoimmune Diseases: Researching and developing therapies for autoimmune and inflammatory conditions.
Leadership and Structure
Marvin White is the President and CEO. The company has a typical biotech organizational structure with research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Ruxience: A biosimilar to Rituxan (rituximab), used to treat certain blood cancers and autoimmune diseases. Aptevo receives royalties from sales of Ruxience by Pfizer. Competitors: Amgen (MVASI), Sandoz (Rixathon), Celltrion (Truxima).
- Apexigen Collaboration: Aptevo provides services to Apexigen to advance APX005M, a novel CD40 antibody. The revenue from the collaboration is a key financial aspect for the company.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advancements in cancer treatment and autoimmune disease therapies. The market is competitive with many large and small biotech companies.
Positioning
Aptevo is a smaller player focused on leveraging its ADAPTIR platform to create differentiated immunotherapies and collaborations. They are focusing on Hematology and other related diseases
Total Addressable Market (TAM)
The TAM for immunotherapies is estimated to be in the hundreds of billions of dollars. Aptevo's positioning focuses on niche areas within this larger market, allowing them to compete by focusing on their innovative technology platform
Upturn SWOT Analysis
Strengths
- ADAPTIR platform technology
- Expertise in antibody engineering
- Strategic collaborations
- Focused on high-growth immunotherapy market
Weaknesses
- Limited financial resources
- Dependence on collaborations
- Early-stage product pipeline
- Small market capitalization
Opportunities
- Expanding partnerships with larger pharmaceutical companies
- Advancing pipeline candidates through clinical trials
- Acquiring or licensing complementary technologies
- Government grants and funding for research
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- MRK
- BMY
- ABBV
Competitive Landscape
Aptevo competes with larger pharmaceutical companies in the immunotherapy space, relying on its ADAPTIR platform to create novel therapies. They must continue to differentiate themselves from the larger firms through novel and innovative technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on milestones and revenues from collaborations.
Future Projections: Future growth depends on the successful development and commercialization of pipeline candidates and the securing of new partnerships.
Recent Initiatives: Focus on advancing core pipeline assets and seeking strategic partnerships.
Summary
Aptevo Therapeutics is a development-stage biotech company with an innovative technology platform but limited financial resources. Its success hinges on advancing its pipeline through clinical trials and securing strategic partnerships to create shareholder value. The company needs to be careful about cash burn. Their dependence on collaborations makes them vulnerable to market and partnership headwinds.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.